Related references
Note: Only part of the references are listed.Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients
Joanna Socha et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 19972010
Francesca Nava et al.
NEURO-ONCOLOGY (2014)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2014)
An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
Giuseppe Lombardi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy
Alessandro Paccapelo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
L. C. Hygino da Cruz et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
Raffaele Addeo et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
